Los Angeles – September 23, 2026 -- Armata Pharmaceuticals has received an additional $3.7 million in non-dilutive funding from the U.S. Department of War, pushing cumulative government support for its lead bacteriophage candidate AP-SA02 to approximately $32.4 million.

Los Angeles – September 17, 2026 -- The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Armata Pharmaceuticals' AP-SA02, an intravenous multi-phage candidate for complicated Staphylococcus aureus bacteremia, stacking the designation atop existing Fast Track and Qualified Infectious Disease Product status.

Los Angeles – September 08, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) said a peer-reviewed paper in the Journal of Molecular Biology has mapped near-atomic resolution structures of eleven proteins in its Ar-KM bacteriophage, a Pseudomonas aeruginosa-targeting phage tied to the company's late-stage AP-PA02 program.